Rondy Marc, Launay Odile, Castilla Jesus, Costanzo Simona, Puig-Barberà Joan, Gefenaite Giedre, Larrauri Amparo, Rizzo Caterina, Pitigoi Daniela, Syrjänen Ritva K, Machado Ausenda, Kurečić Filipović Sanja, Krisztina Horváth Judit, Paradowska-Stankiewicz Iwona, Marbus Sierk, Moren Alain
EpiConcept, Paris, France.
Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France; CIC De Vaccinologie, Cochin-Pasteur, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Vaccine. 2017 Aug 3;35(34):4298-4306. doi: 10.1016/j.vaccine.2017.06.088. Epub 2017 Jul 11.
In Europe, annual influenza vaccination is recommended to elderly. From 2011 to 2014 and in 2015-16, we conducted a multicentre test negative case control study in hospitals of 11 European countries to measure influenza vaccine effectiveness (IVE) against laboratory confirmed hospitalised influenza among people aged ≥65years. We pooled four seasons data to measure IVE by past exposures to influenza vaccination. We swabbed patients admitted for clinical conditions related to influenza with onset of severe acute respiratory infection ≤7days before admission. Cases were patients RT-PCR positive for influenza virus and controls those negative for any influenza virus. We documented seasonal vaccination status for the current season and the two previous seasons. We recruited 5295 patients over the four seasons, including 465A(H1N1)pdm09, 642A(H3N2), 278 B case-patients and 3910 controls. Among patients unvaccinated in both previous two seasons, current seasonal IVE (pooled across seasons) was 30% (95%CI: -35 to 64), 8% (95%CI: -94 to 56) and 33% (95%CI: -43 to 68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Among patients vaccinated in both previous seasons, current seasonal IVE (pooled across seasons) was -1% (95%CI: -80 to 43), 37% (95%CI: 7-57) and 43% (95%CI: 1-68) against influenza A(H1N1)pdm09, A(H3N2) and B respectively. Our results suggest that, regardless of patients' recent vaccination history, current seasonal vaccine conferred some protection to vaccinated patients against hospitalisation with influenza A(H3N2) and B. Vaccination of patients already vaccinated in both the past two seasons did not seem to be effective against A(H1N1)pdm09. To better understand the effect of repeated vaccination, engaging in large cohort studies documenting exposures to vaccine and natural infection is needed.
在欧洲,建议老年人每年接种流感疫苗。在2011年至2014年以及2015 - 16年期间,我们在11个欧洲国家的医院开展了一项多中心检测阴性病例对照研究,以衡量流感疫苗对65岁及以上人群实验室确诊的住院流感的有效性(IVE)。我们汇总了四个季节的数据,通过过去接种流感疫苗的情况来衡量IVE。我们对因与流感相关的临床病症入院、入院前≤7天出现严重急性呼吸道感染的患者进行拭子采样。病例为流感病毒RT-PCR检测呈阳性的患者,对照为任何流感病毒检测呈阴性的患者。我们记录了当前季节以及前两个季节的季节性疫苗接种状况。在这四个季节中,我们招募了5295名患者,其中包括465例甲型(H1N1)pdm09流感、642例甲型(H3N2)流感、278例乙型流感病例患者以及3910名对照。在前两个季节均未接种疫苗的患者中,当前季节性IVE(各季节汇总)对甲型(H1N1)pdm09流感、甲型(H3N2)流感和乙型流感分别为30%(95%置信区间:-35至64)、8%(95%置信区间:-94至56)和33%(95%置信区间:-43至68)。在前两个季节均接种疫苗的患者中,当前季节性IVE(各季节汇总)对甲型(H1N1)pdm09流感、甲型(H3N2)流感和乙型流感分别为-1%(95%置信区间:-80至43)、37%(95%置信区间:7至57)和43%(95%置信区间:1至68)。我们的结果表明,无论患者近期的疫苗接种史如何,当前季节性疫苗都为接种疫苗的患者提供了一定保护,使其免受甲型(H3N2)流感和乙型流感住院感染。在前两个季节均已接种疫苗的患者接种疫苗似乎对甲型(H1N1)pdm09流感无效。为了更好地理解重复接种疫苗的效果,需要开展大型队列研究,记录疫苗接种和自然感染情况。